Cell Death Modulation by Intravenous Immunoglobulin
- 313 Downloads
The induction of cell death in immune cells by naturally occurring antibodies specific for death receptors may present an important antiinflammatory mechanism of intravenous immunoglobulin (IVIG). Conversely, the protection of tissue cells from death receptor-mediated apoptosis by blocking antibodies is thought to contribute to the beneficial effects of IVIG in certain inflammatory disorders such as toxic epidermal necrolysis, also known as Lyell's syndrome. In this review, we focus on recent insights into the role of functional antibodies against Fas, sialic acid-binding immunoglobulin-like lectin (Siglec)-8, and Siglec-9 receptors in IVIG-mediated cell survival or death effects. In addition, we examine a variety of factors in inflammatory disease that may interplay with these cellular events and influence the therapeutic efficacy or potency of IVIG. These involve activation status of the target cell, cytokine microenvironment, pathogenesis and stage of disease, individual genetic determinants, species characteristics, and batch-to-batch variations of IVIG preparations.
KeywordsIntravenous immunoglobulin IVIG autoimmunity immunoregulation Fas Siglec-8 Siglec-9
This work was supported by grants from the Swiss National Science Foundation (310000-107526) and CSL Behring AG, Bern, Switzerland. We thank Aldona Liechti for the illustration.
- 12.von Gunten S, Bochner BS. Expression and function of Siglec-8 in human eosinophils, basophils, and mast cells. In: Pawankar R, Holgate ST, Rosenwasser LJ, editors. Allergy frontiers: classification and pathomechanisms. Tokyo, Japan: Springer; 2009. p. 297–231.Google Scholar
- 22.Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781–90.PubMedGoogle Scholar
- 31.Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. PNAS. 2006;103:7765–70.Google Scholar
- 45.Takigawa N, Kawata N, Shibayama T, Tada A, Kimura G, Munemasa M, et al. Successful treatment of a patient with severe Churg–Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma. 2005;42:639–41.CrossRefPubMedGoogle Scholar
- 48.Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol. 2004;173:6841–68419.PubMedGoogle Scholar